| SCIENCE NEWS | Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-Cell Non-Hodgkin Lymphoma Cellular Biomedicine Group Inc. announced results from an ongoing Phase IIa clinical trial evaluating the safety, feasibility and anti-tumor activity of its acquired chimeric antigen receptor-modified T-cells (CAR-T) immunotherapy (CBM-CD20.1) targeting CD20 for the treatment of patients with advanced B-cell non-Hodgkin lymphoma. [Press release from Cellular Biomedicine Group Inc. discussing research presented at the 4th International Conference on Translational Medicine, Baltimore] Press Release UCART19: First in Man Proof of Concept to Be Presented Cellectis announced that Great Ormond Street Hospital and University College London will present encouraging data from a first in man clinical use of UCART19. [Press release from Cellectis Inc. discussing research to be presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release Immune Design Presents Preclinical Data on G100 and ZVex™ in Combination with Check Point Inhibitors Immune Design announced new preclinical data showing that a dendritic-cell targeting lentiviral vector from its ZVex™ immunotherapy platform administered with G100, which contains a potent synthetic TLR4 agonist, synergize with immune check point inhibitors and demonstrate potent local and systemic anti-tumor activity in cancer models. [Press release from Immune Design discussing research presented at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC), National Harbor] Press Release Intensity Therapeutics Preclinical Results Show AntiCancer Synergy of INT230-6 with Anti-PD-1 Compounds Intensity Therapeutics, Inc. presented preclinical results from a study of INT230-6 in combination with checkpoint inhibitors. The results showed significantly increased antitumor response using a combination of INT230-6 with an anti-PD-1 antibody compared to combined administration of anti-PD-1 and anti-CTLA-4 antibodies. [Press release from Intensity Therapeutics, Inc. discussing research presented at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC), National Harbor] Press Release Biothera to Present Three Abstracts at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Biothera’s Imprime PGG, a safe and systemically administered pathogen associated molecular pattern, initiates an integrated immune response with the potential to dramatically boosts the efficacy of checkpoint inhibitors and other anti-tumor monoclonal antibodies for cancer cell killing and long-term disease control. [Press release from Biothera, The Immune Health Company discussing research to be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston] Press Release |
|